Checklist for the distribution of patients into risk groups for metabolically associated fatty liver disease: features of use in the hospital admissions department
- Authors: Borsukov A.V.1, Venidiktova D.Y.1, Borsukov S.A.2, Ivanov P.A.1, Petuhov I.V.3
-
Affiliations:
- Smolensk State Medical University, the Ministry of Health of the Russian Federation
- Clinical City Hospital No. 1
- Clinical Emergency Hospital
- Issue: Vol 25, No 4 (2023)
- Pages: 20-24
- Section: Note to the nurse
- URL: https://journals.eco-vector.com/0025-8342/article/view/508743
- DOI: https://doi.org/10.29296/25879979-2023-04-04
- ID: 508743
Cite item
Open Access
Access granted
Abstract
Relevance: due to the widespread prevalence of obesity, metabolic syndrome and associated fatty liver disease, as well as due to the lack of an integrated approach to diagnosing the components of metabolically associated fatty liver disease, it is necessary to search for the possibility of early diagnosis already at the level of the admission department of a multidisciplinary hospital.
Objective: to evaluate the effectiveness of the checklist used in the distribution of patients into risk groups for metabolically associated fatty liver disease in tne hospital admissions department.
Materials and methods: in 2019 - 2022 the study was conducted of patients with overweight or obesity (n=74) according to anthropometric data, admitted for treatment to a multidisciplinary hospital in the following profiles: gastroenterology, cardiology, surgery, pulmonology, of which 41 women (55.4%), 33 men (44.6%), mean age 42±4.2 years. For the distribution of patients into groups, taking into account the risk factor for the occurrence of metabolically associated fatty liver disease, a checklist developed for this study with a score and quantitative ultrasound steatometry of the liver was used.
Results and Discussion: correlation of quantitative ultrasound steatometry data with a comprehensive assessment of the presence of metabolic syndrome according to the checklist corresponds to r=0.85 (in the 1st group of patients); r=0.76 (in the 2nd group of patients); r=0.89 (in the 3rd group patients). In the control group 1, patients of the admission department with normal body weight (number of points according to the checklist no more than 2) were examined - liver steatosis without signs of inflammatory activity and liver fibrosis was detected in 7 patients (15.9%).
Conclusions: the use of a checklist by paramedical staff for assigning patients to risk groups for metabolically associated fatty liver disease can reduce the time to detect the disease at an early stage, as well as reduce the time to detect the disease at an early stage, as well as reduce excessive unreasonable workload on ultrasound and radiation diagnostics units.
Full Text
About the authors
Alexey V. Borsukov
Smolensk State Medical University, the Ministry of Health of the Russian Federation
Author for correspondence.
Email: bor55@yandex.ru
ORCID iD: 0000-0003-4047-7252
the Head of Fundamental research laboratory “Diagnostic researches and minimally invasive technologies”, MD, Professor
Russian Federation, 214019, Smolensk, Krupskoy street, 28Daria Yu. Venidiktova
Smolensk State Medical University, the Ministry of Health of the Russian Federation
Email: daria@venidiktova.ru
ORCID iD: 0000-0001-5497-1476
senior scientist of Fundamental research laboratory “Diagnostic researches and minimally invasive technologies”, PhD
Russian Federation, 214019, Smolensk, Krupskoy street, 28Semen A. Borsukov
Clinical City Hospital No. 1
Email: semen.borsukov99@gmail.com
ORCID iD: 0000-0002-5747-6048
ical brother of the Department of Diagnostic and Minimally Invasive Technologies
Russian Federation, 214006, Smolensk, Frunze street, 40Pavel A. Ivanov
Smolensk State Medical University, the Ministry of Health of the Russian Federation
Email: pashkaivashka@mail.ru
ORCID iD: 0009-0005-2924-6287
medical brother of the Department of Diagnostic and Minimally Invasive Technologies, Fundamental research laboratory “Diagnostic researches and minimally invasive technologies”
Russian Federation, 214019, Smolensk, Krupskoy street, 28Ivan V. Petuhov
Clinical Emergency Hospital
Email: gr_lya0615@mail.ru
ORCID iD: 0009-0003-6053-264X
medical brother of the Department of Intensive Care
Russian Federation, 214000, Smolensk, Tenisheva street, 9References
- Винницкая Е. В., Сандлер Ю. Г., Бордин Д. С. Новая парадигма неалкогольной жировой болезни печени: фенотипическое многообразие метаболически ассоциированной жировой болезни печени. Эффективная фармакотерапия. 2020; 16(24): 54–63. doi: 10.33978/2307-3586-2020-16-24-54-63. – EDN SFYLEN.
- Биек А. Ю., Саитов А. Р., Добрынина И. Ю. и др. Метаболически ассоциированная неалкогольная жировая болезнь печени. Вестник СурГУ. Медицина. 2021. 49(3): 14–19. doi: 10.34822/2304-9448-2021-3-14-19. – EDN HRTQOM.
- Nolan P. B., Carrick-Ranson G., Stinear J. W. et al. Prevalence of metabolic syndrome and metabolic syndrome components in young adults: A pooled analysis. Отчеты по профилактической медицине. 2017; 7: 211–215. doi: 10.1016/j.pmedr.2017.07.004. – EDN YGWMRR.
- Вильсон И., Беленькая Л. В., Шолохов Л. Ф. и др. Метаболический синдром: эпидемиология, критерии диагностики, расовые особенности. Acta Biomedica Scientifica (East Siberian Biomedical Journal). 2021; 6(4): 180–191. doi: 10.29413/ABS.2021-6.4.16. – EDN AZSJDE.
- Венидиктова Д. Ю., Горбатенко О. А., Ковалев А. А. и др. Лучевая диагностика метаболического синдрома у пациентов мужского пола с неалкогольной жировой болезнью печени. Смоленский медицинский альманах. 2020; 1: 63–66. EDN LCHHGP.
- Драпкина О. М., Корнеева О. Н. Континуум неалкогольной жировой болезни печени: от стеатоза печени до сердечно-сосудистого риска. Рациональная фармакотерапия в кардиологии. 2016; 12(4): 424–429. doi: 10.20996/1819-6446-2016-12-4-424-429. – EDN WMHLON.
- Хорлампенко А. А., Каретникова В. Н., Кочергина А. М. и др. Индекс висцерального ожирения у пациентов с ишемической болезнью сердца, ожирением и сахарным диабетом 2 типа. Кардиоваскулярная терапия и профилактика. 2020; 19(3): 172–180. doi: 10.15829/1728-8800-2020-2311. – EDN WKXBSO.
- Лазебник Л. Б., Голованова Е. В., Туркина С. В. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;185(1): 4–52. doi: 10.31146/1682-8658-ecg-185-1-4-52.
Supplementary files
